Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022

Rhea-AI Summary

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced a change to the dial-in numbers for its first-quarter financial and operational results conference call on May 10, 2022. The updated numbers are (866) 682-6100 / (862) 298-0702 for U.S. and Canada participants. Additionally, an audio webcast will be accessible via the 'Investors' section on Aurinia's website, with a replay available following the event. Aurinia is known for its FDA-approved oral therapy for treating active lupus nephritis, focusing on serious diseases with high unmet medical needs.

Positive

• Introduction of the first FDA-approved oral therapy for active lupus nephritis.
• Aurinia is positioned as a fully integrated biopharmaceutical company targeting serious diseases.

Negative

• None.

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) announces a change to the dial-in number(s) for the upcoming first quarter financial and operational results announcement on Tuesday, May 10, 2022. The new numbers for interested participants to dial in are: (866) 682-6100 / (862) 298-0702 (Toll-free U.S. & Canada).

The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

About Aurinia

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). Aurinia’s head office is in Victoria, British Columbia; its U.S. commercial hub is in Rockville, Maryland; and the Company focuses development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220506005474/en/

Investor and Corporate Contact

Dana Lynch, IR & Corporate Communications

dlynch@auriniapharma.com

Source: Aurinia Pharmaceuticals Inc.

FAQ

What is the new dial-in number for Aurinia's financial results announcement?

The new dial-in numbers are (866) 682-6100 and (862) 298-0702.

When will Aurinia publish its first-quarter financial results?

Aurinia will announce its first-quarter financial results on May 10, 2022.

Where can I access Aurinia's audio webcast?

The audio webcast can be accessed under 'News/Events' in the 'Investors' section of the Aurinia corporate website.

What significant therapy did Aurinia introduce?

Aurinia introduced the first FDA-approved oral therapy for adult patients with active lupus nephritis.